Molecular Vision: Xu, Mol Vis 2008; 14:1370-1374. Table 3

Table 3. Genotype and allele frequencies in cases with exudative AMD and controls

Genotypes	AMD cases (n=121)	Controls (n=132)	χ²	p value	OR (95%CI)
CFH rs1061170:T>C (Y402H)
Genotype
TT	97 (80.2%)	111 (84.3%)			1.0 (reference)
TC	23 (19.0%)	21 (15.7%)	0.463	0.496	1.25 (0.65-2.40)
CC	1 ( 0.8%)	0 ( 0)	-	-	-
	H-W p=1.0	H-W p=0.843
Allele
T	217 (89.7%)	243 (92.0%)			1.0 (reference)
C	25 (10.3%)	21 ( 8.0%)	0.863	0.353	1.33 (0.73-2.45)
LOC387715 rs10490924:G>T (A69S)
Genotype
GG	18 (14.9%)	40 (30.3%)			1.0 (reference)
GT	49 (40.5%)	70 (53.0%)			1.56 (0.80-3.03)
TT	54 (44.6%)	22 (16.7%)	25.094	<0.001	5.45 (2.59-11.49)
	H-W p=0.283	H-W p=0.480
Allele
G	85 (35.1%)	150 (56.8%)			1.0 (reference)
T	157 (64.9%)	114 (43.2%)	23.89	<0.001	2.43 (1.70-3.48)
HTRA1 rs11200638:G>A
Genotype
GG	13 (10.7%)	44 (33.3%)			1.0 (reference)
GA	52 (43.0%)	64 (48.5%)			2.75 (1.34-5.64)
AA	56 (46.3%)	24 (18.2%)	30.48	<0.001	7.90 (3.61-17.26)
	H-W p=0.980	H-W p=1.0
Allele
G	78 (32.2%)	152 (57.6%)			1.0 (reference)
A	164 (67.8%)	112 (42.4%)	32.711	<0.001	2.82 (1.96-4.06)

This table summarizes the genotype and allele frequencies for the single-nucleotide polymorphisms (SNPs) in complement factor H (CFH), LOC387715, and HTRA1 genes among patients with exudative age-related macular degeneration (AMD) and control subjects. Genotype distributions for SNPs were in Hardy-Weinberg (H-W) equilibrium in either cases or controls. The p-value represents comparison or level of risk significance between AMD cases and controls. Adjustment for multiple comparisons was made using Bonferroni method, which did not change the significant levels for all three SNPs. OR indicates odds ratio and CI refers to confidence interval.